Key Segments
By Type of Diagnostic Test
-
Hormone Tests
-
Luteinizing Hormone (LH)
-
Follicle-Stimulating Hormone (FSH)
-
Testosterone
-
Anti-Müllerian Hormone (AMH)
-
Estrogen
-
-
Blood Tests
-
Fasting Insulin
-
Glucose Tolerance Test
-
Lipid Profile
-
HbA1c
-
-
Imaging Tests
-
Transvaginal Ultrasound
-
Pelvic Ultrasound
-
-
Pelvic Examination
-
Genetic Testing
-
Other Tests (Thyroid Function Tests (TSH, T3, T4), Prolactin Test, DHEAS (Dehydroepiandrosterone Sulfate))
By Drug Class
-
Oral Contraceptives
-
Antiandrogens
-
Insulin-Sensitizing Agents
-
Antidepressants
-
Anti-Obesity Medications
By Surgery Type
-
Ovarian Wedge Resection
-
Laparoscopic Ovarian Drilling (LOD)
By Distribution Channel
-
Hospital Pharmacies
-
Drug Stores & Retail Pharmacies
-
Online Providers
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
Egypt
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g., Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key PCOS diagnostic companies include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Labcorp, Ansh Labs, and Hologic Inc., with a focus on hormone and imaging technologies.
Global demand is shifting toward non-invasive, at-home diagnostics and AI-enabled hormonal analysis, making PCOS screening more accessible and patient-centric.
Increasing cases of insulin resistance, delayed pregnancies, and growing awareness of endocrine disorder diagnostics are major drivers for the PCOS diagnostic market growth.
Hormone assays (like LH, FSH, AMH) and pelvic ultrasounds are the most frequently used diagnostic methods for PCOS due to their clinical accuracy and wide availability.
The PCOS diagnostic market size is expanding steadily due to increased screening and hormonal testing volumes across global healthcare systems. The rising prevalence of PCOS in reproductive-age women continues to drive demand for diagnostics.